当前位置: 首页 >> 检索结果
共有 4447 条符合本次的查询结果, 用时 7.2629064 秒

101. Association of tumor necrosis factor α (rs1800629) and interleukin-10 (rs1800896) gene polymorphisms with systemic lupus erythematosus: a meta-analysis.

作者: Praveen Kumar Chandra Sekar.;Ramakrishnan Veerabathiran.
来源: Reumatologia. 2025年63卷1期41-53页
Systemic lupus erythematosus (SLE) is a complex autoimmune disease influenced by genetic, environmental, and immunological factors. Variations in cytokine genes, including tumor necrosis factor α (TNF-α) and interleukin-10 (IL-10), have been implicated in SLE pathogenesis, but their associations remain uncertain owing to conflicting study results.

102. The relationship between dose of methotrexate and incidence of liver fibrosis in patients with rheumatoid arthritis.

作者: Mina AkbariRad.;Zahra Rezaieyazdi.;Ali Tajik.;Banafshe Ataei.;Mehrdad Sarabi.;Hasan MehradMajd.;Hasan Vossoughinia.;Abdollah Firoozi.
来源: Reumatologia. 2025年63卷1期3-11页
Methotrexate (MTX) is a chemotherapy agent and immune system suppressant that can cause liver fibrosis in long-term usage. This study aimed to investigate the relationship between the dose of MTX and the incidence of liver fibrosis in patients with rheumatoid arthritis (RA).

103. Involving young people in research investigating comorbidity associated with childhood-onset rheumatic disease: perspectives of a series of focus groups.

作者: Sab Siddiq.;Jenny Sammy Ainsworth.;Clare E Pain.;Eve M D Smith.;Sizheng Steven Zhao.;David M Hughes.;Liza J McCann.
来源: BMC Rheumatol. 2025年9卷1期40页
Childhood-onset rheumatic diseases, such as juvenile idiopathic arthritis, juvenile-onset lupus and juvenile dermatomyositis, appear to be associated with an increased risk of comorbidities in adulthood compared to the general population. For the first stage of a research project evaluating this topic, we wanted to capture views from young people with juvenile-onset rheumatic disease to ensure that further work was relevant to their lived experience and priorities. This study aimed to determine (i) which comorbidities young people identify as important, (ii) how they access information about their disease, including comorbidity risk, whether (iii) they would like to hear about the risk of comorbidities whilst they are under paediatric care, and (iv) would be motivated to make lifestyle choices to decrease the risk of potential comorbidities.

104. Vascular liver disorders in patients with antiphospholipid syndrome: a national retrospective multicentre study.

作者: Mathilde Katims.;Marc Pineton de Chambrun.;Cecile Yelnik.;Ada Clarke.;Matthias Papo.;Zahir Amoura.;Marc Lambert.;Pascale Roland-Nicaise.;Aurélie Plessier.;Laure Delaval.;Thomas Papo.;Pierre-Emmanuel Rautou.;Nathalie Costedoat Chalumeau.;Karim Sacre.
来源: Rheumatology (Oxford). 2025年
Antiphospholipid syndrome (APS) is an acquired autoimmune prothrombotic condition. Vascular liver disorders (VLD), such as portal vein thrombosis (PVT), Budd-Chiari syndrome (BCS) and porto-sinusoidal vascular disorder (PSVD), are rare and related to an underlying hypercoagulable state in most cases. We aimed to describe the clinical and immunological features of APS patients with VLD.

105. Risk factors for non-response to initial IVIG plus methylprednisolone therapy in children with Kawasaki disease.

作者: Minna Yang.;Mingming Zhang.;Hongmao Wang.;Xiaohui Li.
来源: Rheumatology (Oxford). 2025年
Intravenous immunoglobulin (IVIG) plus corticosteroids is recommended as the initial intensified therapy for high-risk IVIG-resistant Kawasaki disease (kDa) patients. However, some patients still require additional rescue therapy despite this treatment. This study aimed to identify risk factors associated with non-response to initial IVIG plus methylprednisolone (mPSL) therapy in high-risk refractory kDa patients.

106. Right atrial reservoir strain as an early predictor of pulmonary hypertension development in Systemic Sclerosis: a single center pilot study.

作者: Veronica Codullo.;Mauro Acquaro.;Alessandra Greco.;Micaela Lia.;Bianca Lucia Palermo.;Laura Scelsi.;Sandra Schirinzi.;Annalisa Turco.;Giovanni Zanframundo.;Carlomaurizio Montecucco.;Adele Valentini.;Lorenzo Cavagna.;Stefano Ghio.
来源: Rheumatology (Oxford). 2025年
Regular screening for pulmonary hypertension (PH) is recommended in patients with systemic sclerosis (SSc) for the early detection and treatment of pulmonary arterial hypertension (PAH). Whether Doppler echocardiography may predict subsequent development of PH is still unknown. In this context, there is growing awareness of the potential importance of right atrial (RA) function in reflecting an initial overload of the right heart due to the hypertensive state in the pulmonary circulation is a matter of considerable interest.

107. Executive Summary: The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs.

作者: Sizheng Steven Zhao.;Stephanie R Harrison.;Ben Thompson.;Max Yates.;Joe Eddison.;Antoni Chan.;Nick Clarke.;Nadia Corp.;Charlotte Davis.;Lambert Felix.;Kalveer Flora.;William J Gregory.;Gareth T Jones.;Christopher A Lamb.;Helena Marzo-Ortega.;Daniel J Murphy.;Harry Petrushkin.;Virinderjit Sandhu.;Raj Sengupta.;Stefan Siebert.;Danielle A Van Der Windt.;Dale Webb.;Zenas Z N Yiu.;Karl Gaffney.
来源: Rheumatology (Oxford). 2025年

108. The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs.

作者: Sizheng Steven Zhao.;Stephanie R Harrison.;Ben Thompson.;Max Yates.;Joe Eddison.;Antoni Chan.;Nick Clarke.;Nadia Corp.;Charlotte Davis.;Lambert Felix.;Kalveer Flora.;William J Gregory.;Gareth T Jones.;Christopher A Lamb.;Helena Marzo-Ortega.;Daniel J Murphy.;Harry Petrushkin.;Virinderjit Sandhu.;Raj Sengupta.;Stefan Siebert.;Danielle A Van Der Windt.;Dale Webb.;Zenas Z N Yiu.;Karl Gaffney.
来源: Rheumatology (Oxford). 2025年

109. Responsive and monophasic lupus nephritis: prevalence, associations, and outcomes.

作者: Fadi Kharouf.;Pankti Mehta.;Virginia Carrizo-Abarza.;Qixuan Li.;Laura P Whittall Garcia.;Dafna D Gladman.;Zahi Touma.
来源: Rheumatology (Oxford). 2025年
Lupus nephritis (LN) is associated with significant renal morbidity, although some patients may experience a responsive and monophasic course. We aimed to assess the proportion of LN patients with such a course and identify its associated baseline characteristics.

110. Long-term effectiveness and safety of methotrexate-tacrolimus combination therapy versus methotrexate monotherapy in reducing rheumatoid arthritis flares after TNF inhibitor discontinuation: a retrospective cohort study.

作者: Taio Naniwa.;Mikiko Kajiura.
来源: BMC Rheumatol. 2025年9卷1期39页
This study evaluates the long-term effectiveness and safety of methotrexate-tacrolimus combination therapy compared to methotrexate monotherapy in maintaining successful tumor necrosis factor (TNF) inhibitor discontinuation in rheumatoid arthritis (RA) patients.

111. IgG4-related disease and other fibro-inflammatory conditions.

作者: Francesco Peyronel.;Emanuel Della-Torre.;Federica Maritati.;Maria L Urban.;Ingeborg Bajema.;Nicolas Schleinitz.;Augusto Vaglio.
来源: Nat Rev Rheumatol. 2025年21卷5期275-290页
IgG4-related disease (IgG4-RD) is a fibro-inflammatory disorder usually characterized by multi-organ involvement. Its pathogenesis is complex and involves genetic and environmental factors, while immune responses usually mediate organ damage and promote fibrosis, which is a key feature of the disease. IgG4 responses, however, are not exclusive to IgG4-RD and can be encountered in other diseases with phenotypes that partially overlap that of IgG4-RD. Although IgG4-RD has clinical and histological hallmarks, the lack of validated diagnostic criteria often makes the diagnosis challenging, requiring a multi-dimensional approach that integrates clinical, radiological and serological data. The present Review covers recent advances in the understanding of disease drivers and its clinical phenotypes, mainly focusing on the differential diagnosis with potential IgG4-RD mimickers, namely histiocytoses, lymphoproliferative disorders, systemic vasculitides and other immune-mediated conditions. The Review also provides a schematic approach to IgG4-RD treatment, including a brief overview of glucocorticoid-sparing agents and emerging therapies, from B cell-depleting monoclonal antibodies to cytokine-targeting drugs, the majority of which are currently under investigation in randomized clinical trials.

112. Sex- and gender-based personalized medicine in rheumatology.

作者: Elizabeth R Volkmann.;Carol Feghali-Bostwick.
来源: Nat Rev Rheumatol. 2025年21卷5期251-252页

113. Retraction of: aPKC/Par3/Par6 polarity complexes regulate podocyte motility and crescent formation in the progression of ANCA-associated vasculitis.

来源: Rheumatology (Oxford). 2025年

114. Pneumatosis cystoides intestinalis in overlap syndrome.

作者: May Shuen Tang.;Gim Gee Teng.
来源: Lancet Rheumatol. 2025年

115. Gout: the deeply rooted image of the self-inflicted disease of kings comes from misinterpreting history.

作者: Tristan Pascart.;Emmanuel Drouin.
来源: Lancet Rheumatol. 2025年

116. Serum type I interferon score as a disease activity biomarker in patients with diffuse cutaneous systemic sclerosis: a retrospective cohort study.

作者: Monique Hinchcliff.;Dinesh Khanna.;Enrico De Lorenzis.;Stefano Di Donato.;Antonio Carriero.;Rebecca L Ross.;Suiyuan Huang.;Kathleen A Aren.;Elana J Bernstein.;Mary Carns.;Flavia V Castelino.;Robyn T Domsic.;Tracy M Frech.;Jessica K Gordon.;Faye N Hant.;Ami A Shah.;Victoria K Shanmugam.;Virginia D Steen.;Shervin Assassi.;Francesco Del Galdo.
来源: Lancet Rheumatol. 2025年
Type I interferon (IFN) pathway activation has been associated with severe systemic sclerosis. We aimed to examine the association of serum IFN scores with disease activity and outcomes in two cohorts of patients with diffuse cutaneous systemic sclerosis.

117. Is type I interferon score a promising circulating biomarker for systemic sclerosis?

作者: Yuichiro Shirai.;Masataka Kuwana.
来源: Lancet Rheumatol. 2025年

118. Primary care prediction of hip and knee replacement 1-5 years in advance using temporal graph-based convolutional neural networks (TG-CNNs).

作者: Zoe Hancox.;Sarah R Kingsbury.;Philip G Conaghan.;Andrew Clegg.;Samuel D Relton.
来源: Rheumatology (Oxford). 2025年
This study aimed to predict the risk of requiring a primary hip or knee replacement 1 and 5-years in advance, using Clinical Codes.

119. Is systemic lupus erythematosus, with or without lupus nephritis, different syndromes, and can genetics contribute to the answer?

作者: Lina-Marcela Diaz-Gallo.;Iva Gunnarsson.;Elisabet Svenungsson.
来源: Rheumatology (Oxford). 2025年

120. Clinicopathological features of anti-HMGCR and anti-SRP myopathies that do not satisfy the EULAR/ACR criteria of inflammatory myopathies.

作者: Shogo Komaki.;Akatsuki Kubota.;Asuka Kitamura.;Meiko Maeda.;Masato Kadoya.;Keiichi Hokkoku.;Shunsuke Kobayashi.;Taro Bannai.;Yasushi Shiio.;Naohiro Uchio.;Yoshikazu Uesaka.;Junko Kikuchi.;Izumi Sugimoto.;Takashi Mikata.;Rena Okudera.;Kazushi Suzuki.;Noritoshi Arai.;Yoshio Sakiyama.;Shin-Ichi Tokushige.;Yaeko Ichikawa.;Nobuyuki Yajima.;Ran Nakashima.;Tsuneyo Mimori.;Jun Shimizu.;Toshihiko Komai.;Haruka Tsuchiya.;Keishi Fujio.;Tatsushi Toda.
来源: Rheumatology (Oxford). 2025年
The clinicopathological features of immune-mediated necrotizing myopathy (IMNM) sometimes mimic muscular dystrophy, complicating accurate diagnosis. The European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria of idiopathic inflammatory myopathies (IIMs) are superior in terms of sensitivity and specificity; however, the sensitivity is reported to be relatively low in IMNM. We examined the clinicopathological characteristics and the prognoses of anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) antibody-positive and anti-signal recognition particle (SRP) antibody-positive cases that do not satisfy the EULAR/ACR classification criteria.
共有 4447 条符合本次的查询结果, 用时 7.2629064 秒